Savvidou, I.; Khong, T.; Whish, S.; Carmichael, I.; Sepehrizadeh, T.; Mithraprabhu, S.; Horrigan, S.K.; de Veer, M.; Spencer, A.
Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo. Cancers 2022, 14, 840.
https://doi.org/10.3390/cancers14030840
AMA Style
Savvidou I, Khong T, Whish S, Carmichael I, Sepehrizadeh T, Mithraprabhu S, Horrigan SK, de Veer M, Spencer A.
Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo. Cancers. 2022; 14(3):840.
https://doi.org/10.3390/cancers14030840
Chicago/Turabian Style
Savvidou, Ioanna, Tiffany Khong, Sophie Whish, Irena Carmichael, Tara Sepehrizadeh, Sridurga Mithraprabhu, Stephen K. Horrigan, Michael de Veer, and Andrew Spencer.
2022. "Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo" Cancers 14, no. 3: 840.
https://doi.org/10.3390/cancers14030840
APA Style
Savvidou, I., Khong, T., Whish, S., Carmichael, I., Sepehrizadeh, T., Mithraprabhu, S., Horrigan, S. K., de Veer, M., & Spencer, A.
(2022). Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo. Cancers, 14(3), 840.
https://doi.org/10.3390/cancers14030840
